CN106667962A - Charge conversion type nanometer drug carrier and preparation method thereof - Google Patents
Charge conversion type nanometer drug carrier and preparation method thereof Download PDFInfo
- Publication number
- CN106667962A CN106667962A CN201611261033.7A CN201611261033A CN106667962A CN 106667962 A CN106667962 A CN 106667962A CN 201611261033 A CN201611261033 A CN 201611261033A CN 106667962 A CN106667962 A CN 106667962A
- Authority
- CN
- China
- Prior art keywords
- carrier
- charge conversion
- nano
- electric charge
- conversion hysteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention is suitable for the medicinal technical field and provides a charge conversion type nanometer drug carrier and a preparation method thereof. The charge conversion type nanometer drug carrier comprises an inner core and an outer core, wherein the inner core is served as a carrier main body; the outer core is served as a carrier lock for performing charge conversion on the carrier main body; the inner core and the outer core are combined under the effects of positive and negative charges; the carrier main body is made from the target peptide modified polyethylene glycol-hydrophobic modified chitosan with positive charges; the carrier lock is made from polylysine with the side chain modified with 2,3-dimethyl maleic acid. The charge conversion type nanometer drug carrier provided by the invention has a dual-charge conversion function; the negative charges are loaded on the surface of the charge conversion type nanometer drug carrier; under a weak acid condition, the carrier lock is opened, the carrier charges are reversed, the negative charges are reversed into positive charges, the target peptide is exposed on the micellar surface, a targeting function is achieved and the blood brain barrier is overcome.
Description
Technical field
The invention belongs to pharmaceutical technology field, more particularly to a kind of electric charge conversion hysteria nano-medicament carrier and its preparation side
Method.
Background technology
Nano-medicament carrier is a kind of induction system of the cladding curative drug with nano-scale rank, and it can pass through
Blood circulation enters capillary, extension circulation time in blood flow, also can pass through endothelial cell gap and enters focus, by cell
Absorbed in the way of pinocytosis, realize targeting medication, this helps to reduce dosage, reduces its side effect.Nano-medicament carrier
Particle diameter is smaller, possesses specific surface higher, can embed hydrophobic drug, improves its dissolubility, reduces hydrotropy in routine administration
The side effect of agent；Can advantageously be transported in body, combining for multi-medicament and various methods for diagnosis and treatment can be realized.Nanometer
These advantages of pharmaceutical carrier are that the treatment of some tumor diseases opens new approach.
General pharmaceutical carrier is in blood in cyclic process, if its positively charged is conducive to circulating in blood；Into disease
It is positively charged to be also beneficial to attack sick cell after stove；And there is specific recognition to cortex.However, existing medicine is carried
Body does not all meet above three main points simultaneously, so current pharmaceutical carrier is difficult to overcome blood-brain barrier (BBB).
The content of the invention
The technical problems to be solved by the invention are to provide a kind of electric charge conversion hysteria nano-medicament carrier and its preparation side
Method, it is intended to allow medicine advantageously to be transported in body using electric charge conversion hysteria nano-medicament carrier, is easy to attack lesion thin
Born of the same parents, and to cortex specific recognition.
The present invention is achieved in that a kind of electric charge conversion hysteria nano-medicament carrier, the electric charge conversion hysteria Nano medication
Carrier includes kernel and outer core, and the kernel is carrier element, and the outer core is to carry out electric charge conversion to the carrier element
Carrier latch, the kernel is acted on by positive and negative charge with the outer core and combined；
Polyethylene glycol-hydrophobically modified shitosan that the carrier element is modified for the targeting peptides of positively charged；The carrier latch
The polylysine of 2,3- dimethyl maleic acids is modified for side chain.
Present invention also offers a kind of preparation method of electric charge conversion hysteria nano-medicament carrier described above, including：
Carrier element preparation process：Shitosan is acylated the hydrophobic shitosan of generation, then is grafted the poly- second that end is alkynyl
Glycol (PEG), then with end for the targeting peptides of nitrine are connected by click-reaction (Click reactions), obtains the target of positively charged
To polyethylene glycol-hydrophobically modified shitosan that peptide is modified；
Carrier latch preparation process：Poly- (N ε-benzyloxycarbonyl group lysine) de- benzyloxy is exposed into amino (- NH2), then with 2,3-
Dimethyl maleic anhydride reacts, and obtains the polylysine that side chain modifies 2,3- dimethyl maleic acids；
Nano medication particulate vector preparation process：Will be described using dialysis, reverse evaporation or emulsification mechanism
Polyethylene glycol-hydrophobically modified the shitosan of targeting peptides modification is prepared into nano inner core, then is repaiied side chain by positive and negative charge effect
The polylysin solution for adoring 2,3- dimethyl maleic acids is bundled together with the nano inner core, obtains electric charge conversion hysteria nanometer medicine
Thing carrier.
Present invention also offers a kind of electric charge conversion hysteria Nano medication composition, the electric charge conversion hysteria Nano medication combination
Thing includes carrying medicine kernel and outer core, and the outer core is the carrier latch that electric charge conversion is carried out to the load medicine kernel, in the load medicine
Core is acted on by positive and negative charge with the outer core and combined；
Polyethylene glycol-hydrophobically modified shitosan that the carrier for carrying medicine kernel is modified for the targeting peptides of positively charged, it is described
Medicine is hydrophobic drug, is supported among the carrier；The carrier latch is the poly- of side chain modification 2,3- dimethyl maleic acids
Lysine.
Present invention also offers a kind of preparation method of electric charge conversion hysteria Nano medication composition described above, including：
Carrier element preparation process：Shitosan is acylated the hydrophobic shitosan of generation, then is grafted the poly- second that end is alkynyl
Then glycol is the targeting peptides of nitrine with end by Click reaction formings, obtains the poly- second two of the targeting peptides modification of positively charged
Alcohol-hydrophobically modified shitosan；
Carrier latch preparation process：Poly- (N ε-benzyloxycarbonyl group lysine) de- benzyloxy is exposed into-NH2With 2,3- dimethyl horses
Carry out anhydride reaction, obtain the polylysine that side chain modifies 2,3- dimethyl maleic acids；
Nano medication composition preparation process：By the targeting peptides modify polyethylene glycol-hydrophobically modified shitosan and dredge
Aqueous pharmaceutical is dissolved in organic solvent, is prepared into medicament-carried nano by dialysis, reverse evaporation or emulsification mechanism
Core, then the polylysin solution and the nano inner core bag that side chain is modified 2,3- dimethyl maleic acids are acted on by positive and negative charge
It is rolled in together, obtains electric charge conversion hysteria Nano medication composition.
Compared with prior art, beneficial effect is the present invention：Electric charge conversion hysteria nanometer medicine provided in an embodiment of the present invention
Thing carrier, including the kernel being made up of carrier element and the outer core double-layer structure being made up of carrier latch, and by the carrier
Lock is locked to the carrier.The embodiment of the present invention provides electric charge conversion hysteria nano-medicament carrier, and there is dual electric charge conversion to make
With this electric charge conversion hysteria nano-medicament carrier surface is negatively charged, and under weakly acidic condition, carrier latch is opened, carrier electric charge
Invert, positive charge is converted into by negative electrical charge, targeting peptides are revealed in micellar surface, start to play targeting, overcome blood brain
Barrier.Additionally, carrier is positively charged to be also beneficial to circulate in blood, it is positively charged to be also beneficial to attack disease into after focus
Become cell, and have specific recognition to cortex.
Electric charge conversion hysteria nano-medicament carrier provided in an embodiment of the present invention, allows medicine advantageously to be transported in body
It is defeated, combining for multi-medicament and various methods for diagnosis and treatment is realized, so that for some tumor diseases open new way.
Electric charge conversion hysteria Nano medication composition provided in an embodiment of the present invention, is carried by the electric charge conversion hysteria Nano medication
Body and medicine are constituted, and the medicine is wrapped among the kernel of the electric charge conversion hysteria nano-medicament carrier, and carrier carries medicine
Organized, under weakly acidic condition, carrier latch is opened, carrier electric charge is inverted, positive charge is converted into by negative electrical charge, targetted
Peptide is exposed to micellar surface, starts to play targeting.Carrier is positively charged to be also beneficial to circulate in blood, into focus
Afterwards, it is positively charged to be also beneficial to attack sick cell, and have specific recognition to cortex.Additionally, into after sick cell,
Due to the effect of lysosome, it is smaller that pH becomes, and medicine starts release, so as to start to play drug effect.
Brief description of the drawings
The synthetic route chart of the peptide14-PEG-g-HC that Fig. 1 is provided for second embodiment of the invention；
The synthetic route chart of the D-PLL-DMMA that Fig. 2 is provided for second embodiment of the invention.
Specific embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, it is right below in conjunction with drawings and Examples
The present invention is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, and
It is not used in the restriction present invention.
First embodiment of the invention provides a kind of electric charge conversion hysteria nano-medicament carrier, the electric charge conversion hysteria nanometer medicine
Thing carrier includes kernel and outer core, and the kernel is carrier element, and the outer core is to carry out electric charge conversion to the carrier element
Carrier latch, the kernel and the outer core are acted on by positive and negative charge and combined；
Polyethylene glycol-hydrophobically modified shitosan that the carrier element is modified for the targeting peptides of positively charged；The carrier latch
The polylysine of 2,3- dimethyl maleic acids is modified for side chain.
A kind of electric charge conversion hysteria nano-medicament carrier that first embodiment of the invention is provided, including be made up of carrier element
Kernel and the outer core double-layer structure being made up of carrier latch, and the carrier is locked by the carrier latch.The present invention
Embodiment provides electric charge conversion hysteria nano-medicament carrier has dual electric charge transformation, and this electric charge conversion hysteria Nano medication is carried
Body surface face is negatively charged, and under weakly acidic condition, carrier latch is opened, and carrier electric charge is inverted, and positive electricity is converted into by negative electrical charge
Lotus, targeting peptides are revealed in micellar surface, start to play targeting, overcome blood-brain barrier.Additionally, carrier is positively charged also favourable
It is positively charged to be also beneficial to attack sick cell into after focus in circulating in blood, and have specific knowledge to cortex
Not.
Specifically, the carrier element is connected by hydrophobically modified shitosan, polyethylene glycol and targeting peptides and formed；The carrier
Lock is triggered 1B acid anhydrides (lys-NCA) to carry out active ring-opening polymerisation (ROP polymerizations) and is connected 2,3- dimethyl by initiator
Maleic anhydride (DMMA) and formed.
The modification of chitosan is acyl chitosan, and the acyl group includes caproyl, dodecanoyl or octadecanoyl, preferably
Caproyl；The acylation degree of the acyl chitosan is 0.3~1, preferably 0.5,0.8 or 1.The molecular weight of the shitosan is 5000
~100000.
Specifically, the molecular weight of the polyethylene glycol is 2000~20000, preferably 2000,5000,10000,20000, more
It is preferred that 2000,5000.
Specifically, modification of chitosan in the polyethylene glycol-hydrophobically modified shitosan of the targeting peptides modification of the positively charged, poly-
The mass ratio of ethylene glycol and targeting peptides is 1:(0.02~0.2):(0.05~0.2), preferably 1:0.1:0.05,1:0.05:0.05
Or 1:0.2:0.1.Specifically, the carrier element and the mass ratio of the carrier latch are 0.1~1.4:1, preferably 0.1:1,
0.5:1 or 1:1.The carrier element is different from the mass ratio of the carrier latch, the particle diameter of the nano-medicament carrier of gained, current potential
Size can be different.
Specifically, the targeting peptides 14 are H-THAPMTSPVTP-NH2, H-pwvpswmpprht-NH2, H-thrppmwp-
NH2Or H-T (NMe) H (NMe) RPPM (NMe) WSPVWP-NH2。
First embodiment of the invention provide electric charge conversion hysteria nano-medicament carrier, allow medicine in body advantageously
Transport, realizes combining for multi-medicament and various methods for diagnosis and treatment, so that for some tumor diseases open new way.
Second embodiment of the invention provides a kind of preparation method of electric charge conversion hysteria nano-medicament carrier described above,
Including：
Carrier element preparation process：Shitosan is acylated the hydrophobic shitosan of generation, then is grafted the poly- second that end is alkynyl
Then glycol is the targeting peptides of nitrine with end by Click reaction formings, obtains the poly- second two of the targeting peptides modification of positively charged
Alcohol-hydrophobically modified shitosan；
Carrier latch preparation process：Poly- (N ε-benzyloxycarbonyl group lysine) de- benzyloxy is exposed into-NH2, then with 2,3- dimethyl
Maleic anhydride reacts, and obtains the polylysine that side chain modifies 2,3- dimethyl maleic acids；
Nano medication particulate vector preparation process：Will be described using dialysis, reverse evaporation or emulsification mechanism
Polyethylene glycol-hydrophobically modified the shitosan of targeting peptides modification is prepared into nano inner core, then is repaiied side chain by positive and negative charge effect
The polylysin solution for adoring 2,3- dimethyl maleic acids is bundled together with the nano inner core, obtains electric charge conversion hysteria nanometer medicine
Thing carrier.
Specifically, the carrier element preparation process includes：Shitosan is acylated generation acyl chitosan (HC)；By alkynes
Base-polyethylene glycol-succinimidyl succinate (Propyne-PEG-NHS) reacts with the HC, generates alkynyl-poly- second two
Alcohol-grafting acyl shitosan (Propyne-PEG-g-HC)；The Propyne-PEG-g-HC for reacting generation is led to targeting peptides 14
Click reaction formings are crossed, targeting peptides 14- polyethylene glycol-grafting acyl chitosan (peptide 14-PEG-g-HC) is obtained；
The carrier latch preparation process includes：Two (trichloromethyl) carbonic esters are anti-with N ε-benzyloxy carboxyl -1B
Should, N ε-benzyloxy carboxyl -1B is formed the Lys-NCA of ring-type；Above-mentioned formed ring is triggered to open using initiator
Ring reacts；De- benzyloxy reaction (Deprotection reaction) is carried out, exposes-NH2；- the NH that will expose2Connect 2,3- dimethyl Malaysia
Acid anhydrides (DMMA), obtains diethylamine-polylysine -2,3- dimethyl maleic anhydrides (D-PLL-DMMA)；The initiator, lys-
The mol ratio of NCA and 2,3- dimethyl maleic anhydrides is 1:15~30:3~30, preferably 1:15:10,1:20:10,1:30:10,
1:15:20 or 1:15:30.The initiator includes diethylamine, triethylamine and polyethylene glycol amino (PEG-NH2) at least one
Kind.
The Nano medication particulate vector preparation process includes：Evaporated using dialysis, reverse evaporation or emulsified solvent
Peptide 14-PEG-g-HC is made nano particle by method, is acted on D-PLL-DMMA solution and peptide 14-PEG-g-HC by positive and negative charge
Nano particle is bundled together, and obtains electric charge conversion hysteria nano-medicament carrier.
In carrier element preparation process, the shitosan is carried out into hydrophobic changing by the way that shitosan is acylated into generation HC
Property；Propyne-PEG-NHS is that HC is connected into PEG during generating Propyne-PEG-g-HC with HC reactions, this mistake
PEG is as water-wet side in journey, it is therefore an objective to be self-assembled into micella below.Propyne-PEG-g-HC is connected with targeting peptides 14,
It is Propyne-PEG-g-HC with the azide reaction on peptide.
Specifically, the synthetic route chart of peptide14-PEG-g-HC is referring to Fig. 1, the synthetic route of D-PLL-DMMA referring to
Fig. 2.
Specifically, the mol ratio of poly- (the N ε-benzyloxycarbonyl group lysine) and 2,3- dimethyl maleic anhydrides for (0.05~
2):1。
The preparation method of the electric charge conversion hysteria nano-medicament carrier that second embodiment of the invention is provided, turns according to the electric charge
Remodel the structure composition of nano-medicament carrier, prepare its unique double-decker having, the preparation method is simple to operate, easily
In industrialized production.
Third embodiment of the invention provides a kind of electric charge conversion hysteria Nano medication composition, the electric charge conversion hysteria nanometer
Pharmaceutical composition includes carrying medicine kernel and outer core, and the outer core is the carrier latch that electric charge conversion is carried out to the load medicine kernel, institute
State load medicine kernel and combination is acted on by positive and negative charge with the outer core；
Polyethylene glycol-hydrophobically modified shitosan that the carrier for carrying medicine kernel is modified for the targeting peptides of positively charged, it is described
Medicine is hydrophobic drug, is supported among the carrier；The carrier latch is the poly- of side chain modification 2,3- dimethyl maleic acids
Lysine.
The electric charge conversion hysteria Nano medication composition that third embodiment of the invention is provided, by electric charge conversion hysteria nanometer medicine
Thing carrier and medicine are constituted, and the medicine is wrapped among the kernel of the electric charge conversion hysteria nano-medicament carrier, and carrier is carried
Medicine is organized, and under weakly acidic condition, carrier latch is opened, and carrier electric charge is inverted, and positive charge is converted into by negative electrical charge,
Targeting peptides are exposed to micellar surface, start to play targeting.Carrier is positively charged to be also beneficial to circulate in blood, into disease
It is positively charged to be also beneficial to attack sick cell after stove, and have specific recognition to cortex.Additionally, into sick cell
Afterwards, due to the effect of lysosome, it is smaller that pH becomes, and medicine starts release, so as to start to play drug effect.
Specifically, the electric charge conversion hysteria Nano medication composition is nano particle, when pH is 7.1~7.9, the electricity
The particle size of lotus conversion hysteria Nano medication composition is 50-150nm；When pH is 6.1~6.9, the outer core comes off.
Specifically, when pH is 7.1~7.9, the surface charge of the electric charge conversion hysteria Nano medication composition is weak negative
Electric or not charged, when pH is 6.1~6.9, the surface charge of the electric charge conversion hysteria Nano medication composition is positive charge.
Specifically, the hydrophobic drug includes taxol, Irinotecan, hydrophobic adriamycin, melphalan, Temozolomide
In at least one.The targeting peptides 14 are H-THAPMTSPVTP-NH2, H-pwvpswmpprht-NH2, H-T (NMe) H (NMe)
RPPM(NMe)WSPVWP-NH2Or H-thrppmwp-NH2.The hydrophobic drug and the electric charge conversion hysteria nano-medicament carrier
Mass ratio be 0.1~1:1, preferably 0.4:1 or 0.5:1.
Fourth embodiment of the invention provides a kind of preparation side of electric charge conversion hysteria Nano medication composition described above
Method, including：
Carrier element preparation process：Shitosan is acylated the hydrophobic shitosan of generation, then is grafted the poly- second that end is alkynyl
Then glycol is the targeting peptides of nitrine with end by Click reaction formings, obtains the poly- second two of the targeting peptides modification of positively charged
Alcohol-hydrophobically modified shitosan；
Carrier latch preparation process：Poly- (N ε-benzyloxycarbonyl group lysine) de- benzyloxy is exposed into-NH2With 2,3- dimethyl horses
Carry out anhydride reaction, obtain the polylysine that side chain modifies 2,3- dimethyl maleic acids；
Nano medication composition preparation process：By the targeting peptides modify polyethylene glycol-hydrophobically modified shitosan and dredge
Aqueous pharmaceutical is dissolved in organic solvent, is prepared into medicament-carried nano by dialysis, reverse evaporation or emulsification mechanism
Core, then the polylysin solution and the nano inner core bag that side chain is modified 2,3- dimethyl maleic acids are acted on by positive and negative charge
It is rolled in together, obtains electric charge conversion hysteria Nano medication composition.
Specifically, the mol ratio of poly- (the N ε-benzyloxycarbonyl group lysine) and 2,3- dimethyl maleic anhydrides for (0.05~
2):1。
Fifth embodiment of the invention provides a kind of electric charge conversion hysteria Nano medication granular preparation, and the electric charge conversion hysteria is received
Rice medicine granule for treating includes ultra-pure water and the electric charge conversion hysteria Nano medication group as described above being scattered in the ultra-pure water
Compound.
Specifically, the concentration of the electric charge conversion hysteria Nano medication particle is 0.5-4mg/mL, preferably 1mg/mL, 2mg/mL
Or 3mg/mL.
The electric charge conversion hysteria Nano medication composition that third embodiment of the invention is provided is made medicine granule for treating, it is convenient
User uses, and the curative effect of described pharmaceutical composition is farthest played.
Technical scheme is described further below in conjunction with specific embodiment.
Embodiment 1
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in dimethyl sulfoxide (DMSO) (DMSO) after terminating is reacted, then in deionized water
Middle dialysis 24h (molecule interception is 3500), freezes；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, with 0.1N's (normal concentration)
NaOH solution is slowly added dropwise regulation pH, its pH is balanced between 8~10；DMMA is dividedly in some parts again, is surveyed after DMMA is added every time
Examination pH, is slowly added dropwise the NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8mL hexanoyls are added dropwise
Chlorine.After caproyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；By product
Drop by drop instill in 20mL absolute ethers, be precipitated out, repeat 3~5 times.Centrifugation, centrifugal rotational speed is 2500rpm
(rev/min), abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg hexanoyl chitosan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 2000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 3500), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg tri- (3- hydroxypropyls triazolyl methyl) amine
(THPTA) 24h, is reacted at normal temperatures.Dialysed in the bag filter of the molecular weight 3500 that dams after 3d, freezed, obtain peptide 14-PEG-
G-HC powder.
2. the preparation of electric charge conversion hysteria Nano medication composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows：50mg polymer is dissolved in 5mL first
In alcohol；With 0.45 μm of filter insoluble filtering dust；It is placed in the bag filter of the molecular weight 3500 that dams, in 50mM (mmoles
You have every liter) during pH is 7.4 PBS (PBS), at room temperature, to dialyse 3 days, last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH are 7.4,50mM PBS), and adds medicine, its two drop
Interval time be 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 2
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 48h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 5000), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.The acyls of 8g 18 are added dropwise
Chlorine.After 18 acyl chlorides are all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 2000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 5000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.
Dam and dialyse in the bag filter of molecular weight 3500 after 3d, freeze, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria Nano medication composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows, and 50mg polymer is dissolved in 5mL methyl alcohol
In.With 0.45 μm of filter insoluble filtering dust.It is placed in the bag filter of the molecular weight 3500 that dams, 50mM pH7.4's
In PBS, at room temperature, dialyse 3 days.Last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 3
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 72h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 10000), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 2000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 10000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.
Dam and dialyse in the bag filter of molecular weight 3500 after 3d, freeze, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows, and 50mg polymer is dissolved in 5mL methyl alcohol
In.With 0.45 μm of filter insoluble filtering dust.It is placed in the bag filter of the molecular weight 3500 that dams, is 7.4 in 50mM pH
PBS in, at room temperature, dialyse 3 days.Last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 4
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 3500), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 5000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 1000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mgPEG-g-HC and 100mg N3- peptides 14 are dissolved in
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.Cutting
Dialysed in the bag filter of stream molecular weight 3500 after 3d, freezed, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows, and 50mg polymer is dissolved in 5mL methyl alcohol
In.With 0.45 μm of filter insoluble filtering dust.It is placed in the bag filter of the molecular weight 3500 that dams, 50mM pH7.4's
In PBS, at room temperature, dialyse 3 days.Last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 5
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 3500), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 5000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 1000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mgPEG-g-HC and 100mg N3- peptides 14 are dissolved in
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.Cutting
Dialysed in the bag filter of stream molecular weight 3500 after 3d, freezed, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows, and 50mg polymer is dissolved in 5mL methyl alcohol
In.With 0.45 μm of filter insoluble filtering dust.Drawn with above solution syringe, medicine is placed on the PBS of 50mM
Middle stirring, the night of above syringe is slowly injected in the PBS containing medicine.Last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 6
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 3500), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 5000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 1000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.
Dam and dialyse in the bag filter of molecular weight 3500 after 3d, freeze, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by dialysis.Its specific method is as follows, and 50mg polymer is dissolved in 5mL methyl alcohol
In.With 0.45 μm of filter insoluble filtering dust.It is put into flask, after methyl alcohol is evaporated, is added in the PBS of 50mM and surpasses
Sound, last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 7
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 3500), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 5000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 1000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mgCuBr and 80mg THPTA, 24h is reacted at normal temperatures.Cutting
Dialysed in the bag filter of stream molecular weight 3500 after 3d, freezed, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by emulsification mechanism.Its specific method is as follows, and 50mg polymer is dissolved in
In 5mL methyl alcohol.With 0.45 μm of filter insoluble filtering dust.The water of 0.1ml is added, stirring forms w/o type emulsion,
Again plus relatively large water carries out emulsifying to obtain W/O/W type emulsions for second, re-evaporation removes organic solvent, and last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Embodiment 8
1st, electric charge conversion hysteria pharmaceutical carrier is prepared：
The synthesis of a, D-PLL-DMMA
Weigh during 11.2g N ε-benzyloxy carboxyl -1B solid dissolving is 180mL anhydrous tetrahydro furans；Weigh
5.2g bis- (trichloromethyl) carbonic ester solid is dissolved in 40mL anhydrous tetrahydro furans, is poured into isobaric funnel.In oil bath reaction,
Reaction temperature is maintained at 50 DEG C or so.Two (trichloromethyl) carbonate solutions that will have been dissolved drop by drop instill N ε-benzyloxy
In carboxyl -1B, 1~2h is dripped off, and reacts 0.5h after dripping off completely again.Product revolving is concentrated by evaporation to 20~
30mL.With the anhydrous normal butane precipitated products of 200mL, -4 DEG C of recrystallization 6h suction filtrations, removing filtrate.By suction filtration gained solid in vacuum
Storage at 12h, -20 DEG C is dried in drying box；
In ice-water bath, by (30min in the DMF solution of the diethylamine DMF solution of 20mg/mL instillation Lys-NCA slowly
Drip off), then at normal temperatures, 24h is reacted, the 12h that dialysed in DMSO after terminating is reacted, then dialysis 24h (divides in deionized water
Sub- interception is 3500), to freeze；
First use CF3COOH dissolves P (Lys- benzyloxies), then 33% HBr/CHCOOH is instilled, in ice-water bath, instead
Answer 2h.It is lyophilized；
Polylysine P (Lys) after de- benzyloxy is dissolved in 3mL deionized waters, is slowly dripped with the NaOH solution of 0.1N
Plus regulation pH, its pH is balanced between 8~10.DMMA is dividedly in some parts again, pH is tested after adding DMMA every time, be slowly added dropwise
The NaOH of 0.2N, it is ensured that its pH is balanced between 8~10.
The synthesis of b, peptide 14-PEG-g-HC
2g shitosans are weighed, is added in 20mL pyrovinic acid solution, stirring to shitosan is completely dissolved.8g lauroyls are added dropwise
Chlorine.After lauroyl chloride is all dripped off, balloon is filled with appropriate nitrogen, be inserted on bottle stopper.Magnetic agitation 5h at room temperature；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.It is centrifuged, centrifugal rotational speed is
2500rpm, abandoning supernatant.Then solid product is placed on and 24h is dried in vacuum drying chamber, drying box temperature is set as 35
℃；
Weigh 200mg shellglycan solids to be dissolved in 4mL DMF solution, add the poly- second of 124mg
Glycol-succinimide acetic acid esters (molecular weight 5000), seals bottleneck.The stirring reaction 24h on magnetic stirring apparatus；Reaction is produced
Thing is drop by drop instilled in 20mL absolute ethers, is precipitated out, and is repeated 3~5 times.By products therefrom in deionized water
Dialysis 2 days (molecule interception is 1000), period changes a water every 0.5~1h；
N3- peptides 14 and PEG-g-HC are that, by Click reaction formings, 300mg PEG-g-HC and 100mg N3- peptides 14 are molten
In 20mL deionized waters, continuous nitrogen is passed through, adds 60mg CuBr and 80mg THPTA, 24h is reacted at normal temperatures.
Dam and dialyse in the bag filter of molecular weight 3500 after 3d, freeze, obtain peptide 14-PEG-g-HC powder.
2. the preparation of electric charge conversion hysteria nano pharmaceutical composition
Peptide 14-PEG-g-HC micellas are prepared by reverse evaporation.Its specific method is as follows, and 50mg polymer is dissolved in 5mL
In methyl alcohol.With 0.45 μm of filter insoluble filtering dust.The water of 0.5ml is added, stirring forms w/o type emulsion, then
Evaporating organic solvent, the vesica volume that reverse evaporation is obtained is relatively large, and last solubility is 1mg/mL；
D-PLL-DMMA is dissolved in the PBS that pH is 7.4,50mM (10mg/mL), is filtered with 0.45 μm of filter.By this
Solution is slowly added dropwise in peptide 14-PEG-g-CS micellas (1mg/mL, pH 7.4,50mM PBS), and adds medicine, its two drop
Interval time is 5min.Thus electric charge conversion hysteria Nano medication composition is obtained.
Presently preferred embodiments of the present invention is the foregoing is only, is not intended to limit the invention, it is all in essence of the invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Claims (8)
1. a kind of electric charge conversion hysteria nano-medicament carrier, it is characterised in that in the electric charge conversion hysteria nano-medicament carrier includes
Core and outer core, the kernel are carrier element, and the outer core is the carrier latch that electric charge conversion is carried out to the carrier element, described
Kernel is acted on by positive and negative charge with the outer core and combined；
Polyethylene glycol-hydrophobically modified shitosan that the carrier element is modified for the targeting peptides of positively charged；The carrier latch is side
Chain modifies the polylysine of 2,3- dimethyl maleic acids.
2. electric charge conversion hysteria nano-medicament carrier as claimed in claim 1, it is characterised in that the modification of chitosan is acyl group
Shitosan, the acyl group includes caproyl, dodecanoyl or octadecanoyl, and the acylation degree of the acyl chitosan is 0.3~1.
3. electric charge conversion hysteria nano-medicament carrier as claimed in claim 1, it is characterised in that the molecular weight of the shitosan is
5000~100000.
4. electric charge conversion hysteria nano-medicament carrier as claimed in claim 1, it is characterised in that the molecular weight of the polyethylene glycol
It is 2000-20000.
5. electric charge conversion hysteria nano-medicament carrier as claimed in claim 1, it is characterised in that the carrier element and the load
The mass ratio of body lock is (0.1~1.4):1.
6. electric charge conversion hysteria nano-medicament carrier as claimed in claim 1, it is characterised in that the targeting peptides 14 are H-
THAPMTSPVTP-NH2, H-pwvpswmpprht-NH2, H-thrppmwp-NH2Or H-T (NMe) H (NMe) RPPM (NMe)
WSPVWP-NH2。
7. a kind of preparation method of electric charge conversion hysteria nano-medicament carrier as described in claim 1 to 6 any one, its feature
It is, including：
Carrier element preparation process：Shitosan is acylated the hydrophobic shitosan of generation, then is grafted the polyethylene glycol that end is alkynyl,
Then it is the targeting peptides of nitrine with end by Click reaction formings, obtains the polyethylene glycol of the targeting peptides modification of positively charged-dredge
Water modification of chitosan；
Carrier latch preparation process：Poly- (N ε-benzyloxycarbonyl group lysine) de- benzyloxy is exposed into-NH2, then with 2,3- dimethyl Malaysia
Anhydride reaction, obtains the polylysine that side chain modifies 2,3- dimethyl maleic acids；
Nano medication particulate vector preparation process：Using dialysis, reverse evaporation or emulsification mechanism by the targeting
Polyethylene glycol-hydrophobically modified the shitosan of peptide modification is prepared into nano inner core, then is acted on side chain modification 2 by positive and negative charge,
The polylysin solution of 3- dimethyl maleic acids is bundled together with the nano inner core, obtains electric charge conversion hysteria Nano medication and carries
Body.
8. the preparation method of electric charge conversion hysteria nano-medicament carrier as claimed in claim 7, it is characterised in that it is described it is poly- (N ε-
Benzyloxycarbonyl group lysine) with the mol ratio of 2,3- dimethyl maleic anhydrides it is (0.05~2):1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611261033.7A CN106667962B (en) | 2016-12-30 | 2016-12-30 | Charge conversion type nano-drug carrier and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611261033.7A CN106667962B (en) | 2016-12-30 | 2016-12-30 | Charge conversion type nano-drug carrier and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106667962A true CN106667962A (en) | 2017-05-17 |
| CN106667962B CN106667962B (en) | 2019-12-13 |
Family
ID=58850098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611261033.7A Active CN106667962B (en) | 2016-12-30 | 2016-12-30 | Charge conversion type nano-drug carrier and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106667962B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109265680A (en) * | 2018-09-21 | 2019-01-25 | 中国科学院理化技术研究所 | PH-responsive epsilon-polylysine and preparation method and application thereof |
| CN111939268A (en) * | 2019-05-14 | 2020-11-17 | 南京中医药大学 | Nano particle compound for responsive deformation of tumor microenvironment |
| CN116162255A (en) * | 2022-12-18 | 2023-05-26 | 东莞理工学院 | Charge-convertible dendrimer and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103182087A (en) * | 2011-12-30 | 2013-07-03 | 沈阳药科大学 | Trimethyl chitosan-graft-polyethylene glycol/nucleic acid brain-targeting micellar and preparation method thereof |
-
2016
- 2016-12-30 CN CN201611261033.7A patent/CN106667962B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103182087A (en) * | 2011-12-30 | 2013-07-03 | 沈阳药科大学 | Trimethyl chitosan-graft-polyethylene glycol/nucleic acid brain-targeting micellar and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| ROGER PRADES,: "applying the retro-enantio approach to obtain a peptide capable of overcoming the blood-brain barrier", 《ANGEWANDTE CHEMIE INTERNATIONAL EDITION》 * |
| 严瑶瑶: "一种新型的基于电荷转换的抗血脑屏障药物载体的制备研究", 《2016年全国高分子材料科学与工程研讨会论文摘要集》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109265680A (en) * | 2018-09-21 | 2019-01-25 | 中国科学院理化技术研究所 | PH-responsive epsilon-polylysine and preparation method and application thereof |
| CN109265680B (en) * | 2018-09-21 | 2021-04-16 | 中国科学院理化技术研究所 | PH-responsive epsilon-polylysine and preparation method and application thereof |
| CN111939268A (en) * | 2019-05-14 | 2020-11-17 | 南京中医药大学 | Nano particle compound for responsive deformation of tumor microenvironment |
| CN111939268B (en) * | 2019-05-14 | 2023-03-31 | 南京中医药大学 | Nano particle compound for responsive deformation of tumor microenvironment |
| CN116162255A (en) * | 2022-12-18 | 2023-05-26 | 东莞理工学院 | Charge-convertible dendrimer and preparation method thereof |
| CN116162255B (en) * | 2022-12-18 | 2024-07-09 | 东莞理工学院 | Charge-convertible dendrimer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106667962B (en) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101327328B (en) | Dendrimers targeting nano particle and preparation and application thereof | |
| CN108017783B (en) | Polymer and the preparation method and application thereof with high potency drugs load performance | |
| CN106667962A (en) | Charge conversion type nanometer drug carrier and preparation method thereof | |
| CN102120756A (en) | Taxol-based small molecule hydrogel-nanosphere transmission system and preparation method thereof | |
| CN103396521B (en) | The synthesis of amphipathic beta-cyclodextrin star-type polymer and micellization application thereof | |
| CN103550781A (en) | Self-assembled dendrimer drug carrier, and preparation method and application thereof | |
| CN103251561A (en) | Double-sensitive disintegrating nano-sized vesica medicine carrier preparation and preparation method thereof | |
| Shi et al. | Polyelectrolyte complex nanoparticles based on chitosan and methoxy poly (ethylene glycol) methacrylate-co-poly (methylacrylic acid) for oral delivery of ibuprofen | |
| CN106692108A (en) | Charge transfer type nano pharmaceutical composition and preparation method thereof | |
| Zhou et al. | Engineering polyzwitterion with acylsulfonamide-based betaine structure for protonated switch of surface chemistry at tumoral pH and reductive responsive drug release of polymeric micelles | |
| CN113827567B (en) | Application of polymer vesicle carrying small molecular medicine in preparation of medicine for treating acute stranguria leukemia | |
| CN110859825B (en) | Preparation method of targeted drug delivery nano-delivery system | |
| Wang et al. | Self-assembled dehydropeptide nanocarrier as a delivery system for antitumor drug temozolomide | |
| CN108084377A (en) | One kind has H2O2Block polymer of response and its preparation method and application | |
| CN107693505A (en) | Double dissolubility ROS sensitive nanoparticles of a kind of new profit and preparation method thereof | |
| CN104224721B (en) | Sensitively responsive polymer nano-particles, and preparation method and application thereof | |
| CN105168230B (en) | A kind of cancer target prodrug and its nanometer formulation and preparation method with endosome escape function | |
| CN108359052A (en) | A kind of gambogicacid-folic acid-HPMA high molecular polymers and its preparation method and application | |
| CN104523716A (en) | Pharmaceutical composition as well as preparation method and use thereof | |
| CN107619473B (en) | Method for removing DMAP (dimethyl acetamide) in synthesis of grafted cholesterol amphiphilic polymer material | |
| CN103977417A (en) | Preparation method of amphiphilic drug-loaded nanoparticles | |
| CN103976948A (en) | Polymer medicament containing polyacrylic acid | |
| CN104001182A (en) | Novel antitumor doxorubicin-containing macromolecular drug | |
| CN104001184A (en) | Macromolecule doxorubicin bonding medicine and preparing method thereof | |
| CN101002942A (en) | PEG type elaioplast nanometer particle medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210415 Address after: 518000 18-c, unit 2, building 5, Haojing City, No.8, democracy Avenue, Ho Township Community, Shajing street, Bao'an District, Shenzhen City, Guangdong Province Patentee after: Haisi Meiyu (Shenzhen) Technology Co.,Ltd. Address before: 518000 No. 3688 Nanhai Road, Shenzhen, Guangdong, Nanshan District Patentee before: SHENZHEN University |